Late adriamycin-related cardiotoxicity of dose-dense and intense sequential doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.

被引：0
|
作者：
Abu-Khalaf, M [1 ]
Juneja, V [1 ]
Chung, G [1 ]
DiGiovanna, M [1 ]
Wackers, F [1 ]
Lee, F [1 ]
Burtness, B [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S109 / S110
页数：2
相关论文
共 50 条
  • [31] Dose-dense taxotere (T) and adriamycin/cyclophosphamide (AC) as neoadjuvant treatment in locally advanced breast cancer (LABC).
    García-Mata, J
    Calvo, L
    García-Palomo, A
    Mel, JR
    Almanza, MC
    Ramos, M
    de Paz, LH
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S226 - S227
  • [32] Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
    Moebus, Volker
    Jackisch, Christian
    Lueck, Hans-Joachim
    du Bois, Andreas
    Thomssen, Christoph
    Kurbacher, Christian
    Kuhn, Walther
    Nitz, Ulrike
    Schneeweiss, Andreas
    Huober, Jens
    Harbeck, Nadia
    von Minckwitz, Gunter
    Runnebaum, Ingo B.
    Hinke, Axel
    Kreienberg, Rolf
    Konecny, Gottfried E.
    Untch, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : 2874 - 2880
  • [33] A retrospective study of dose-dense adjuvant paclitaxel without G-CSF support in patients with breast cancer.
    Singh, Anurag Kumar
    Malhotra, Akshiv
    Lemke, Sheila M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first line chemotherapy, in advanced breast cancer.
    Fountzilas, G
    Papadimitriou, C
    Bafaloukos, D
    Skarlos, D
    Kalofonos, HP
    Aravantinos, G
    Papakostas, P
    Kosmidis, P
    Pavlidis, N
    Dimopoulos, MA
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 26 - 26
  • [35] Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
    van Rossum, A. G. J.
    Kok, M.
    van Werkhoven, E.
    Opdam, M.
    Mandjes, I. A. M.
    van Leeuwen-Stok, A. E.
    van Tinteren, H.
    Imholz, A. L. T.
    Portielje, J. E. A.
    Bos, M. M. E. M.
    van Bochove, A.
    Wesseling, J.
    Rutgers, E. J.
    Linn, S. C.
    Oosterkamp, H. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 102 : 40 - 48
  • [36] Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer
    McArthur, H. L.
    Rugo, H.
    Paulson, M.
    Rourke, M.
    Traina, T.
    Panageas, K.
    Steingart, R.
    Dang, C.
    Fornier, M.
    Park, J.
    Moasser, M.
    Melisko, M.
    Sugarman, S.
    Norton, L.
    Hudis, C. A.
    Dickler, M. N.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S147 - S148
  • [37] Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
    Foldi, Julia
    Silber, Andrea
    Reisenbichler, Emily
    Singh, Kamaljeet
    Fischbach, Neal
    Persico, Justin
    Adelson, Kerin
    Katoch, Anamika
    Horowitz, Nina
    Lannin, Donald
    Chagpar, Anees
    Park, Tristen
    Marczyk, Michal
    Frederick, Courtney
    Burrello, Trisha
    Ibrahim, Eiman
    Qing, Tao
    Bai, Yalai
    Blenman, Kim
    Rimm, David L.
    Pusztai, Lajos
    [J]. NPJ BREAST CANCER, 2021, 7 (01)
  • [38] Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes
    Hudis, CA
    Seidman, AD
    Baselga, J
    Raptis, G
    Lebwohl, D
    Gilewski, T
    Currie, V
    Moynahan, ME
    Sklarin, N
    Fennelly, D
    Uhlenhopp, M
    Riedel, E
    Yao, TJ
    Norton, L
    [J]. SEMINARS IN ONCOLOGY, 1995, 22 (06) : 18 - 23
  • [39] The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Dang, Chau
    Fornier, Monica
    Sugarman, Steven
    Troso-Sandoval, Tiffany
    Lake, Diana
    D'Andrea, Gabriella
    Seidman, Andrew
    Sklarin, Nancy
    Dickler, Maura
    Currie, Violante
    Gilewski, Theresa
    Moynahan, Mary Ellen
    Drullinsky, Pamela
    Robson, Mark
    Wasserheit-Leiblich, Carolyn
    Mills, Nancy
    Steingart, Richard
    Panageas, Katherine
    Norton, Larry
    Hudis, Clifford
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1216 - 1222
  • [40] Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
    Julia Foldi
    Andrea Silber
    Emily Reisenbichler
    Kamaljeet Singh
    Neal Fischbach
    Justin Persico
    Kerin Adelson
    Anamika Katoch
    Nina Horowitz
    Donald Lannin
    Anees Chagpar
    Tristen Park
    Michal Marczyk
    Courtney Frederick
    Trisha Burrello
    Eiman Ibrahim
    Tao Qing
    Yalai Bai
    Kim Blenman
    David L. Rimm
    Lajos Pusztai
    [J]. npj Breast Cancer, 7
12345